ANVS Annovis Bio Inc.

36.66
-0.75  -2%
Previous Close 37.41
Open 36.9
52 Week Low 4.14
52 Week High 132
Market Cap $296,966,896
Shares 8,100,570
Float 5,639,681
Enterprise Value $279,400,574
Volume 625,586
Av. Daily Volume 1,296,182
Stock charts supplied by TradingView

Upcoming Catalysts

Drug Stage Catalyst Date
ANVS401
Alzheimer’s disease (AD) and Parkinson’s disease (PD)
Phase 2
Phase 2
Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 14-day FREE TRIAL.

Latest News

  1. New York, New York--(Newsfile Corp. - August 2, 2021) - Wolf Popper LLP is investigating potential securities fraud claims on behalf of purchasers of Annovis Bio, Inc. common stock (NYSE:ANVS).

    Annovis is a clinical-drug company and its lead drug candidate is ANVS401 (a/k/a Posiphen), which is used to treat Parkinson's and Alzheimer's diseases. Annovis is conducting two Phase 2 clinical trials with Posiphen. One trial is only for Alzheimer's patients and the other trial is for both Alzheimer's and Parkinson's patients.

    Wolf Popper's investigation is focused on whether Annovis misled its investors about Posiphen's efficacy in treating Alzheimer's and Parkinson's Diseases.

    On May 21, 2021, Annovis announced positive results from one if its Posiphen…

    New York, New York--(Newsfile Corp. - August 2, 2021) - Wolf Popper LLP is investigating potential securities fraud claims on behalf of purchasers of Annovis Bio, Inc. common stock (NYSE:ANVS).

    Annovis is a clinical-drug company and its lead drug candidate is ANVS401 (a/k/a Posiphen), which is used to treat Parkinson's and Alzheimer's diseases. Annovis is conducting two Phase 2 clinical trials with Posiphen. One trial is only for Alzheimer's patients and the other trial is for both Alzheimer's and Parkinson's patients.

    Wolf Popper's investigation is focused on whether Annovis misled its investors about Posiphen's efficacy in treating Alzheimer's and Parkinson's Diseases.

    On May 21, 2021, Annovis announced positive results from one if its Posiphen trials for treatment of Alzheimer's patients. As a result, Annovis's stock price increased over 127% and closed at $60.00 per share.

    On July 28, 2021, Annovis attended the 2021 Alzheimer's Association International Conference and presented new clinical trial data for Posiphen that failed to show statistical significance in treating Alzheimer's and Parkinson's patients relative to a placebo. On this news, Annovis's stock price collapsed $65.94 per share, or over 60%, and closed at $43.50 per share.

    For more information, Annovis investors with trading losses of over $50,000 and who would like to learn more about Wolf Popper's investigation should contact Joshua Ruthizer at (212) 451-9668 or at .

    Wolf Popper has successfully recovered billions of dollars for defrauded investors. Wolf Popper's reputation and expertise have been repeatedly recognized by the courts, which have appointed the firm to major positions in securities litigation. For more information about Wolf Popper, please visit the Firm's website at www.wolfpopper.com.

    Attorney Advertising: Prior Results Do Not Guarantee A Similar Outcome.

    Wolf Popper LLP
    Joshua Ruthizer
    845 Third Avenue
    New York, NY 10022
    Tel.: (212) 451-9668
    Email:

    To view the source version of this press release, please visit https://www.newsfilecorp.com/release/91878

    View Full Article Hide Full Article
  2. ANVS401's Interim Clinical Data Demonstrate Statistically Significant Improvements in Cognitive Function in AD Patients and Motor Function in PD Patients

    Biomarkers Demonstrate Reduction in Neurotoxic Proteins, Improvement in Axonal Health and Reduction in Inflammation Levels

    Next Clinical Data Readout Expected in the Third Quarter

    Berwyn, Pennsylvania--(Newsfile Corp. - July 30, 2021) - Annovis Bio, Inc. (NYSE:ANVS), a clinical-stage drug platform company addressing Alzheimer's disease (AD), Parkinson's disease (PD) and other neurodegenerative diseases, today said it is pleased by the positive interim results released on July 28 from Phase II clinical trials of its lead compound, ANVS401 (Posiphen).

    Over the course of the first 25 days of treatment…

    ANVS401's Interim Clinical Data Demonstrate Statistically Significant Improvements in Cognitive Function in AD Patients and Motor Function in PD Patients

    Biomarkers Demonstrate Reduction in Neurotoxic Proteins, Improvement in Axonal Health and Reduction in Inflammation Levels

    Next Clinical Data Readout Expected in the Third Quarter

    Berwyn, Pennsylvania--(Newsfile Corp. - July 30, 2021) - Annovis Bio, Inc. (NYSE:ANVS), a clinical-stage drug platform company addressing Alzheimer's disease (AD), Parkinson's disease (PD) and other neurodegenerative diseases, today said it is pleased by the positive interim results released on July 28 from Phase II clinical trials of its lead compound, ANVS401 (Posiphen).

    Over the course of the first 25 days of treatment, the initial patient cohorts demonstrated statistically significant positive results in both their cognitive and motor skills. The biomarkers presented and analyzed to date also corroborate the efficacy of ANVS401.

    Maria L. Maccecchini, Ph.D., Founder, CEO and President of Annovis Bio, said, "We were pleased to see improvements in cognition and motor skills in only 25 days and are hopeful we will see cumulative and long-lasting positive outcomes from the use of ANVS401 through the remainder of the trials."

    Additional results include:

    • AD Patients: In the ongoing study of ADAS-Cog, the ANVS401-treated group showed improvement in all four ADAS-Cog tests performed compared to the placebo group. Specifically, patients treated with ANVS401 showed a 4.7 point or 30% improvement while the placebo group showed a 1.1 point improvement in ADAS-Cog11. Additionally, the WAIS coding test, which measures speed in movement and thinking, found that treated AD patients had a 6.6 point improvement in coding after ANVS401 treatment. In AD patients there were positive trends in MMSE and total CDR score, but the data was not statistically significant.
    • PD Patients: In the ongoing study of MDS-UPDRS test, the ANVS401-treated group showed improvement in all four parts of UPDRS test compared to the placebo group. Specifically, PD patients treated with ANVS401 improved 6.2 points (14%) while the placebo group declined 4.2 points. Additionally, the WAIS coding test, which measures speed in movement and thinking, showed that PD patients had a 6.1-point improvement in coding after ANVS401 treatment.

    The trial also measured the levels of six neurotoxic aggregating proteins, levels of neurofilament light to show axonal health and of three inflammatory markers that are prevalent in the brains of AD and PD patients. All of the neurotoxic proteins were reduced in AD patients - some reductions were statistically significant, and some were not. Neurofilament light was reduced in both AD and PD patients compared to placebo, although the results were not statistically significant. All of the inflammatory markers showed statistically significant reductions after 25 days of treatment in 14 PD patients. In addition, we determined there was a statistically significant increase in the ratio of Aβ42/Aβ40 among AD patients, suggesting that they improved.

    The company expects its next clinical data readout in the third quarter and plans to release the outcome of its review of all the biomarkers of the toxic cascade in the coming months.

    About Annovis Bio Inc.

    Headquartered in Berwyn, Pennsylvania, Annovis Bio, Inc. (Annovis) is a clinical-stage, drug platform company addressing neurodegeneration, such as Alzheimer's disease (AD), Parkinson's disease (PD) and Alzheimer's in Down Syndrome (AD-DS). We believe that we are the only company developing a drug for AD, PD and AD-DS that inhibits more than one neurotoxic protein and, thereby, improves the information highway of the nerve cell, known as axonal transport. When this information flow is impaired, the nerve cell gets sick and dies. We have two ongoing Phase 2 studies: one in AD patients and one in both AD and PD patients. In the AD/PD study our drug improves memory loss and dementia associated with AD, as well as body and brain function in PD. For more information on Annovis, please visit the company's website: www.annovisbio.com.

    Forward-Looking Statements

    Statements in this press release contain "forward-looking statements" that are subject to substantial risks and uncertainties. Forward-looking statements contained in this press release may be identified by the use of words such as "anticipate," "expect," "believe," "will," "may," "should," "estimate," "project," "outlook," "forecast" or other similar words, and include, without limitation, statements regarding the timing, effectiveness, and anticipated results of ANVS401 clinical trials. Forward-looking statements are based on Annovis Bio, Inc.'s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully in the section titled "Risk Factors" in the Annual Report on Form 10-K for the year ended December 31, 2020 filed with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date, and Annovis Bio, Inc. undertakes no duty to update such information except as required under applicable law.

    Contacts

    Investor Relations:
    Dave Gentry, CEO
    RedChip Companies Inc.
    407-491-4498

    Media:
    Devin Broda/Kate Gorgi
    Sard Verbinnen & Co

    To view the source version of this press release, please visit https://www.newsfilecorp.com/release/91701

    View Full Article Hide Full Article
  3. NEW YORK, July 30, 2021 /PRNewswire/ -- Prominent investor rights law firm Bernstein Litowitz Berger & Grossmann LLP ("BLB&G") is investigating potential violations of the federal securities laws by Annovis Bio, Inc. ("Annovis" or the "Company") (NYSE:ANVS).

    BLB&G is investigating whether Annovis misled investors regarding the efficacy of its Alzheimer's drug, Posiphen.

    Annovis is a clinical-stage biotechnology company developing treatments for neurodegenerative diseases. The Company's lead candidate is Posiphen, or ANVS401, an orally administered drug that purportedly inhibits the production of neurotoxic proteins that lead to neurodegeneration. Annovis is currently testing Posiphen in two Phase 2 clinical trials for the treatment of Alzheimer's Disease and Parkinson's Disease.

    BLB&G's investigation is focused on whether Annovis misled investors about Posiphen's efficacy in treating patients with Alzheimer's and Parkinson's Diseases.

    On July 28, 2021, after the market closed, Annovis reported clinical trial data for Posiphen that failed to show statistical significance in treating Alzheimer's and Parkinson's Disease patients relative to a placebo.  On this news, Annovis' stock price declined $65.94 per share, or over 60%.

    The investigation is being led by BLB&G partners Avi Josefson and Scott R. Foglietta. Annovis investors who suffered a loss and would like to learn more about our investigation, please contact BLB&G at (212) 554-4444, via e-mail at , or through the form on our website at https://www.blbglaw.com/cases-investigations/annovis-bio-inc.

    About BLB&G

    BLB&G is widely recognized worldwide as a leading law firm advising institutional investors on issues related to corporate governance, shareholder rights, and securities litigation.  Since its founding in 1983, BLB&G has built an international reputation for excellence and integrity and pioneered the use of the litigation process to achieve precedent-setting governance reforms. Unique among its peers, BLB&G has obtained several of the largest and most significant securities recoveries in history, recovering over $33 billion on behalf of defrauded investors. More information about the firm can be found online at www.blbglaw.com.

    This press release may be considered Attorney Advertising under the applicable law and ethics rules of some jurisdictions. Prior results do not guarantee a similar outcome.

    Contact

    Avi Josefson

    Scott R. Foglietta

    Bernstein Litowitz Berger & Grossmann LLP

    1251 Avenue of the Americas, 44th Floor

    New York, New York 10020

    (212) 554-4444

             

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/investigation-alert-bernstein-litowitz-berger--grossmann-llp-announces-investigation-of-annovis-bio-inc-and-encourages-investors-to-contact-the-firm-301344991.html

    SOURCE Bernstein Litowitz Berger & Grossmann LLP

    View Full Article Hide Full Article
  4. Berwyn, Pennsylvania--(Newsfile Corp. - July 28, 2021) - Annovis Bio, Inc. (NYSE:ANVS) ("Annovis" or the "Company"), a clinical-stage drug platform company addressing Alzheimer's disease (AD), Parkinson's disease (PD) and other neurodegenerative diseases, with data from two phase 2 studies showing its lead compound improves cognition in AD patients and motor function in PD patients, is presenting new clinical efficacy and biomarker data of its drug ANVS401 during a one hour panel presentation, beginning at 8:00 p.m. ET today, July 28, at the 2021 Alzheimer's Association International Conference (AAIC) in Denver, Colorado.

    The first part of the panel will feature Cheng Fang, PhD, Annovis Bio's VP of Research, an expert in axonal transport and…

    Berwyn, Pennsylvania--(Newsfile Corp. - July 28, 2021) - Annovis Bio, Inc. (NYSE:ANVS) ("Annovis" or the "Company"), a clinical-stage drug platform company addressing Alzheimer's disease (AD), Parkinson's disease (PD) and other neurodegenerative diseases, with data from two phase 2 studies showing its lead compound improves cognition in AD patients and motor function in PD patients, is presenting new clinical efficacy and biomarker data of its drug ANVS401 during a one hour panel presentation, beginning at 8:00 p.m. ET today, July 28, at the 2021 Alzheimer's Association International Conference (AAIC) in Denver, Colorado.

    The first part of the panel will feature Cheng Fang, PhD, Annovis Bio's VP of Research, an expert in axonal transport and protein aggregation. Dr. Fang will present the mechanism of action and will be followed by William Mobley, PhD, Distinguished Professor, Department of Neurosciences, and the Florence Riford Chair for Alzheimer's Research at the University of California San Diego, who will discuss how axonal transport explains the efficacy of ANVS401 in two very different patient populations, AD and PD.

    The second part of the panel discussion will feature the clinical study and clinical data of the first 28 patients treated with ANVS401 in the Company's ongoing Phase 2a trials. The data will be presented by Priscilla Hernandez, Founder of Ezy Medical Research Co., who recruited and treated nearly one-third of the 68 patients in the two studies, and Maria L. Maccecchini, PhD, CEO of Annovis Bio and principal investigator of the studies.

    The table below shows the biomarkers measured to date and how ANVS401 reverses the toxic cascade, starting with lowering levels of neurotoxic proteins, improving the health of the axon, lowering inflammation, and improving cognition and motor function. It further shows the efficacy seen in AD patients by ADAS-Cog11 and in PD patients by MDS-UPDRS, as well as the efficacy seen in both patient populations using the WAIS coding test.

    Cannot view this image? Visit: https://orders.newsfilecorp.com/files/7656/91498_eb77347444ef4bd7_001.jpg

    Figure 1

    To view an enhanced version of Figure 1, please visit:
    https://orders.newsfilecorp.com/files/7656/91498_eb77347444ef4bd7_001full.jpg

    To view the data presented by Dr. Maccecchini at AAIC, please visit:

    https://irpages2.eqs.com/websites/annovis/English/4000/investors-_-media.html#events

    About Annovis Bio Inc.

    Headquartered in Berwyn, Pennsylvania, Annovis Bio, Inc. (Annovis) is a clinical-stage, drug platform company addressing neurodegeneration, such as Alzheimer's disease (AD), Parkinson's disease (PD) and Alzheimer's in Down Syndrome (AD-DS). We believe that we are the only company developing a drug for AD, PD and AD-DS that inhibits more than one neurotoxic protein and, thereby, improves the information highway of the nerve cell, known as axonal transport. When this information flow is impaired, the nerve cell gets sick and dies. We have two ongoing Phase 2 studies: one in AD patients and one in both AD and PD patients. In the AD/PD study our drug improves memory loss and dementia associated with AD, as well as body and brain function in PD. For more information on Annovis, please visit the company's website: www.annovisbio.com.

    Forward-Looking Statements

    Statements in this press release contain "forward-looking statements" that are subject to substantial risks and uncertainties. Forward-looking statements contained in this press release may be identified by the use of words such as "anticipate," "expect," "believe," "will," "may," "should," "estimate," "project," "outlook," "forecast" or other similar words, and include, without limitation, statements regarding the timing, effectiveness, and anticipated results of ANVS401 clinical trials. Forward-looking statements are based on Annovis Bio, Inc.'s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully in the section titled "Risk Factors" in the Annual Report on Form 10-K for the year ended December 31, 2020 filed with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date, and Annovis Bio, Inc. undertakes no duty to update such information except as required under applicable law.

    Investor Relations:
    Dave Gentry, CEO
    RedChip Companies Inc.
    407-491-4498

    To view the source version of this press release, please visit https://www.newsfilecorp.com/release/91498

    View Full Article Hide Full Article
  5. New efficacy and biomarker data to be featured in panel presentation on Wednesday, July 28. A poster presentation featuring positive clinical outcome data from the Company's two Phase 2a studies will be available on Monday, July 26

    Berwyn, Pennsylvania--(Newsfile Corp. - July 23, 2021) - Annovis Bio, Inc. (NYSE:ANVS) ("Annovis" or the "Company"), a clinical-stage drug platform company addressing Alzheimer's disease (AD), Parkinson's disease (PD) and other neurodegenerative diseases, with data from two phase 2 studies showing its lead compound improves cognition in AD patients and motor function in PD patients, today announced that it will present new data for its lead product candidate, ANVS401, at the 2021 Alzheimer's Association International…

    New efficacy and biomarker data to be featured in panel presentation on Wednesday, July 28. A poster presentation featuring positive clinical outcome data from the Company's two Phase 2a studies will be available on Monday, July 26

    Berwyn, Pennsylvania--(Newsfile Corp. - July 23, 2021) - Annovis Bio, Inc. (NYSE:ANVS) ("Annovis" or the "Company"), a clinical-stage drug platform company addressing Alzheimer's disease (AD), Parkinson's disease (PD) and other neurodegenerative diseases, with data from two phase 2 studies showing its lead compound improves cognition in AD patients and motor function in PD patients, today announced that it will present new data for its lead product candidate, ANVS401, at the 2021 Alzheimer's Association International Conference (AAIC), which is being held in Denver, Co and virtually, from July 26 through July 30.

    On Wednesday, July 28, at 8 p.m. ET, Annovis Bio will host a panel presentation which will include new efficacy and biomarker data from an interim analysis of the Company's ongoing Phase 2a trials. The data presented will include:

    • Neurotoxic protein levels
    • Marker of axonal damage
    • Inflammatory markers
    • Efficacy

    "We are excited to share our latest data at AAIC as we continue to advance our novel approach to treating Alzheimer's disease," stated Maria L. Maccecchini, Ph.D., CEO of Annovis Bio.

    ANVS401 will also be featured in a poster presentation: Positive Clinical Outcomes in Two Phase 2a Studies: ADAS-Cog in Alzheimer's and MDS-UPDRS in Parkinson's patients plus Markers of Toxic Cascade that Leads to Nerve Cell Death.

    Previously, Annovis Bio reported that AD patients treated with ANVS401 for 25 days showed a statistically significant 30% cognitive improvement as measured by the Alzheimer's Disease Assessment Scale-Cognitive Subscale 11 (ADAS-Cog11); PD patients treated with ANVS401 showed a statistically significant 18% motor function improvement as measured by the MDS-UPDRS. Additionally, in a test that measures speed and accuracy, AD and PD patients both responded with a statistically significant increase in correctly coded fields. The Company also measured inflammatory factors and found statistically significant lowering of these factors. These tests were part of the Company's ongoing Phase 2a study in AD and PD patients.

    About Annovis Bio Inc.

    Headquartered in Berwyn, Pennsylvania, Annovis Bio, Inc. (Annovis) is a clinical-stage, drug platform company addressing neurodegeneration, such as Alzheimer's disease (AD), Parkinson's disease (PD) and Alzheimer's in Down Syndrome (AD-DS). We believe that we are the only company developing a drug for AD, PD and AD-DS that inhibits more than one neurotoxic protein and, thereby, improves the information highway of the nerve cell, known as axonal transport. When this information flow is impaired, the nerve cell gets sick and dies. We have two ongoing Phase 2 studies: one in AD patients and one in both AD and PD patients. In the AD/PD study our drug improves memory loss and dementia associated with AD, as well as body and brain function in PD. For more information on Annovis, please visit the company's website: www.annovisbio.com.

    Forward-Looking Statements

    Statements in this press release contain "forward-looking statements" that are subject to substantial risks and uncertainties. Forward-looking statements contained in this press release may be identified by the use of words such as "anticipate," "expect," "believe," "will," "may," "should," "estimate," "project," "outlook," "forecast" or other similar words, and include, without limitation, statements regarding the timing, effectiveness, and anticipated results of ANVS401 clinical trials. Forward-looking statements are based on Annovis Bio, Inc.'s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully in the section titled "Risk Factors" in the Annual Report on Form 10-K for the year ended December 31, 2020 filed with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date, and Annovis Bio, Inc. undertakes no duty to update such information except as required under applicable law.

    Investor Relations:
    Dave Gentry, CEO
    RedChip Companies Inc.
    407-491-4498

    To view the source version of this press release, please visit https://www.newsfilecorp.com/release/91067

    View Full Article Hide Full Article
View All Annovis Bio Inc. News